氟伐他汀对慢性心力衰竭患者心功能、炎症因子及预后的影响

【目的】观察氟伐他汀对慢性心力衰竭患者预后的影响及治疗后炎症因子的改变。【方法】慢性心力衰竭住院患者89例，随机分成氟伐他汀观察组（45例），对照组（44例）。两组患者均按常规治疗，观察组加用氟伐他汀40mg，每晚1次，治疗12周后复查高敏C反应蛋白（HS—CRP）、肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）及测量左室射血分数（LVEF），评估心功能。【结果】治疗12周后，观察组较治疗前及对照组Hs-CRP、TNF-α、IL-6均有明显的降低（P〈0．05），LVEF则有明显提高（P〈0．05）。随访2年，观察组病死率明显降低（P〈0．01）。【结论】氟伐他汀治疗慢性心力衰竭能够改善患者的预后及降低炎症因子。

Clinical Observation on Fluvastatin for Improving Prognosis and Changes Of Inflammatory Factors In Patients with Chronic Heart Failure

[Objective] To observe the effects of fluvastatin on the prognosis of patients with chronic heart failure and to investigate the changes of serum levels of inflammatory factors after treatment. [Methods] A total of 89 patients with chronic heart failure were randomly divided into fluvastatin observation group （ n = 45） and the control group（ n =44）. All patientsreceived conventional treatment, and the observation group received conventional treat- ment plus fluvastatin 40mg/d （once a night）. After treatment of 12 weeks, high sensitivity C-reactive protein（HsCRP）, tumor necrosis factor-α（TNF-a）, interleukin-6（IL-6） and left ventricular ejection fraction （LVEF） of cardiac were examined, and the cardiac function was also evaluated. [Results] After treatment of 12 weeks, serum Hs-CRP, TNF-α and IL-6 in the observation group decreased at varying degrees in comparison with control group（ P 〈0.05）. Furthermore, LVEF significantly improved （ P 〈0.05）. With 2-year follow-up, the case-fatality rate in the observation group decreased rapidly （ P 〈0. 01）. [Conclusion] Fluvastatin can improve the prognosis and reduce the levels of serum inflammatory factors of patients with chronic heart failure.